Drugs / KITE-222
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04789408 | Jul 2021 → May 2024 | acute myeloid leukemia | Kite, A Gilead Company | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KITE-222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04789408 ↗ |
| Modality | Cell therapy | “Autologous Anti-CLL-1 CAR T-cell Therapy” NCT04789408 ↗ |
| Route | Intravenous | “A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously” NCT04789408 ↗ |